{"id":"https://openalex.org/W4383755513","doi":"https://doi.org/10.1182/bloodadvances.2022008207","title":"Targeting conditioned media dependencies and FLT-3 in chronic lymphocytic leukemia","display_name":"Targeting conditioned media dependencies and FLT-3 in chronic lymphocytic leukemia","publication_year":2023,"publication_date":"2023-07-10","ids":{"openalex":"https://openalex.org/W4383755513","doi":"https://doi.org/10.1182/bloodadvances.2022008207","pmid":"https://pubmed.ncbi.nlm.nih.gov/37428863","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/10558618"},"language":"en","primary_location":{"id":"doi:10.1182/bloodadvances.2022008207","doi":"https://doi.org/10.1182/bloodadvances.2022008207","is_oa":true,"landing_page_url":"https://doi.org/10.1182/bloodadvances.2022008207","pdf_url":"https://ashpublications.org/bloodadvances/article-pdf/doi/10.1182/bloodadvances.2022008207/2063042/bloodadvances.2022008207.pdf","source":{"id":"https://openalex.org/S2764683450","display_name":"Blood Advances","issn_l":"2473-9529","issn":["2473-9529","2473-9537"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-1","ki-jl-2","medline","norway-1","oarl","poland-40","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood Advances","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://ashpublications.org/bloodadvances/article-pdf/doi/10.1182/bloodadvances.2022008207/2063042/bloodadvances.2022008207.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5051693135","display_name":"Salma Parvin","orcid":"https://orcid.org/0000-0001-6111-1212","observed_orcids":["https://orcid.org/0000-0001-6111-1212"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Salma Parvin","raw_affiliation_strings":["1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":"https://orcid.org/0000-0001-6111-1212","affiliations":[{"raw_affiliation_string":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047569698","display_name":"Aditi Aryal","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Aditi Aryal","raw_affiliation_strings":["1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068829110","display_name":"Shanye Yin","orcid":"https://orcid.org/0000-0001-9116-5238","observed_orcids":["https://orcid.org/0000-0001-9116-5238"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Shanye Yin","raw_affiliation_strings":["1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA","2Harvard Medical School, Boston, MA"],"raw_orcid":"https://orcid.org/0000-0001-9116-5238","affiliations":[{"raw_affiliation_string":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]},{"raw_affiliation_string":"2Harvard Medical School, Boston, MA","institution_ids":["https://openalex.org/I136199984"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023833214","display_name":"Geoffrey G. Fell","orcid":"https://orcid.org/0000-0001-6436-6691","observed_orcids":["https://orcid.org/0000-0001-6436-6691"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Geoffrey G. Fell","raw_affiliation_strings":["1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063755644","display_name":"Matthew Steven Davids","orcid":"https://orcid.org/0000-0003-4529-2003","observed_orcids":["https://orcid.org/0000-0003-4529-2003"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Matthew S. Davids","raw_affiliation_strings":["1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047701430","display_name":"Catherine J. Wu","orcid":"https://orcid.org/0000-0002-3348-5054","observed_orcids":["https://orcid.org/0000-0002-3348-5054"]},"institutions":[{"id":"https://openalex.org/I107606265","display_name":"Broad Institute","ror":"https://ror.org/05a0ya142","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I107606265"]},{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Catherine J. Wu","raw_affiliation_strings":["1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA","2Harvard Medical School, Boston, MA","3Broad Institute of MIT and Harvard, Cambridge, MA","Harvard Medical School, Boston, Massachusetts, United States"],"raw_orcid":"https://orcid.org/0000-0002-3348-5054","affiliations":[{"raw_affiliation_string":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]},{"raw_affiliation_string":"2Harvard Medical School, Boston, MA","institution_ids":["https://openalex.org/I136199984"]},{"raw_affiliation_string":"3Broad Institute of MIT and Harvard, Cambridge, MA","institution_ids":["https://openalex.org/I107606265"]},{"raw_affiliation_string":"Harvard Medical School, Boston, Massachusetts, United States","institution_ids":["https://openalex.org/I136199984"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5022857112","display_name":"Anthony G. Letai","orcid":"https://orcid.org/0000-0002-1993-9013","observed_orcids":["https://orcid.org/0000-0002-1993-9013"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Anthony Letai","raw_affiliation_strings":["1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA","2Harvard Medical School, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]},{"raw_affiliation_string":"2Harvard Medical School, Boston, MA","institution_ids":["https://openalex.org/I136199984"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5022857112"],"corresponding_institution_ids":["https://openalex.org/I136199984","https://openalex.org/I4210117453"],"apc_list":{"value":3000,"currency":"USD","value_usd":3000},"apc_paid":{"value":3000,"currency":"USD","value_usd":3000},"fwci":1.0208,"has_fulltext":true,"cited_by_count":5,"citation_normalized_percentile":{"value":0.76674914,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":90,"max":97},"biblio":{"volume":"7","issue":"19","first_page":"5877","last_page":"5889"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10950","display_name":"Acute Lymphoblastic Leukemia research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/chronic-lymphocytic-leukemia","display_name":"chronic lymphocytic leukemia","score":1.0},{"id":"https://openalex.org/keywords/tumor-microenvironment","display_name":"tumor microenvironment","score":0.7160000205039978},{"id":"https://openalex.org/keywords/stromal-interactions","display_name":"stromal interactions","score":0.6669999957084656},{"id":"https://openalex.org/keywords/mcp-1","display_name":"MCP-1","score":0.9490000009536743},{"id":"https://openalex.org/keywords/flt3-inhibitors","display_name":"FLT3 inhibitors","score":0.7170000076293945},{"id":"https://openalex.org/keywords/cd135","display_name":"CD135","score":0.9330000281333923},{"id":"https://openalex.org/keywords/ighv-mutation-status","display_name":"IGHV mutation status","score":0.7179999947547913},{"id":"https://openalex.org/keywords/focal-adhesion-signaling","display_name":"focal adhesion signaling","score":0.8029999732971191},{"id":"https://openalex.org/keywords/ras-signaling","display_name":"Ras signaling","score":0.9800000190734863},{"id":"https://openalex.org/keywords/apoptosis-resistance","display_name":"apoptosis resistance","score":0.515999972820282},{"id":"https://openalex.org/keywords/drug-resistance","display_name":"drug resistance","score":0.8140000104904175}],"concepts":[{"id":"https://openalex.org/C2777938653","wikidata":"https://www.wikidata.org/wiki/Q1088156","display_name":"Chronic lymphocytic leukemia","level":3,"score":0.8720334768295288},{"id":"https://openalex.org/C16930146","wikidata":"https://www.wikidata.org/wiki/Q4381253","display_name":"Stromal cell","level":2,"score":0.6955782175064087},{"id":"https://openalex.org/C2779675984","wikidata":"https://www.wikidata.org/wiki/Q23671272","display_name":"Venetoclax","level":4,"score":0.6872273087501526},{"id":"https://openalex.org/C2777609679","wikidata":"https://www.wikidata.org/wiki/Q5971015","display_name":"IGHV@","level":4,"score":0.6754472851753235},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5908414721488953},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.5618675947189331},{"id":"https://openalex.org/C2779878957","wikidata":"https://www.wikidata.org/wiki/Q5984881","display_name":"Ibrutinib","level":4,"score":0.5328180193901062},{"id":"https://openalex.org/C2776107976","wikidata":"https://www.wikidata.org/wiki/Q1786433","display_name":"Tumor microenvironment","level":3,"score":0.46175122261047363},{"id":"https://openalex.org/C26291073","wikidata":"https://www.wikidata.org/wiki/Q310484","display_name":"Ex vivo","level":3,"score":0.4367449879646301},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.4244269132614136},{"id":"https://openalex.org/C190283241","wikidata":"https://www.wikidata.org/wiki/Q14599311","display_name":"Apoptosis","level":2,"score":0.41837549209594727},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.39176881313323975},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.29099881649017334},{"id":"https://openalex.org/C3020616263","wikidata":"https://www.wikidata.org/wiki/Q1216998","display_name":"Tumor cells","level":2,"score":0.08400559425354004},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007135","descriptor_name":"Immunoglobulin Variable Region","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D007135","descriptor_name":"Immunoglobulin Variable Region","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D015398","descriptor_name":"Signal Transduction","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015451","descriptor_name":"Leukemia, Lymphocytic, Chronic, B-Cell","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":true},{"descriptor_ui":"D017077","descriptor_name":"Culture Media, Conditioned","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D051941","descriptor_name":"fms-Like Tyrosine Kinase 3","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D059016","descriptor_name":"Tumor Microenvironment","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1182/bloodadvances.2022008207","doi":"https://doi.org/10.1182/bloodadvances.2022008207","is_oa":true,"landing_page_url":"https://doi.org/10.1182/bloodadvances.2022008207","pdf_url":"https://ashpublications.org/bloodadvances/article-pdf/doi/10.1182/bloodadvances.2022008207/2063042/bloodadvances.2022008207.pdf","source":{"id":"https://openalex.org/S2764683450","display_name":"Blood Advances","issn_l":"2473-9529","issn":["2473-9529","2473-9537"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-1","ki-jl-2","medline","norway-1","oarl","poland-40","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood Advances","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:10558618","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/10558618","pdf_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC10558618/pdf/main.pdf","source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood Adv","raw_type":"Text"},{"id":"pmid:37428863","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/37428863","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood advances","raw_type":"Journal Article"}],"best_oa_location":{"id":"doi:10.1182/bloodadvances.2022008207","doi":"https://doi.org/10.1182/bloodadvances.2022008207","is_oa":true,"landing_page_url":"https://doi.org/10.1182/bloodadvances.2022008207","pdf_url":"https://ashpublications.org/bloodadvances/article-pdf/doi/10.1182/bloodadvances.2022008207/2063042/bloodadvances.2022008207.pdf","source":{"id":"https://openalex.org/S2764683450","display_name":"Blood Advances","issn_l":"2473-9529","issn":["2473-9529","2473-9537"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-1","ki-jl-2","medline","norway-1","oarl","poland-40","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood Advances","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9763000011444092}],"study_designs":[],"awards":[{"id":"https://openalex.org/G6825946319","display_name":"Defining the impact of mutational drivers on the immune microenvironment of CLL","funder_award_id":"R21CA267527","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G9000866778","display_name":"Comprehensive dissection of the CLL genome & phenome to improve patient outcomes","funder_award_id":"P01CA206978","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G9000875973","display_name":"Reading mitochondrial apoptotic signaling to identify active cancer therapeutics","funder_award_id":"R35CA242427","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G9000877998","display_name":"Physician Scientist Training in Cancer Research","funder_award_id":"T32CA009172","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"}],"funders":[{"id":"https://openalex.org/F4320308573","display_name":"Gilead Sciences","ror":"https://ror.org/056546b03"},{"id":"https://openalex.org/F4320313971","display_name":"TG Therapeutics","ror":"https://ror.org/00pwykz63"},{"id":"https://openalex.org/F4320316491","display_name":"MEI Pharma","ror":"https://ror.org/02bgfrc80"},{"id":"https://openalex.org/F4320319131","display_name":"Ascentage Pharma","ror":"https://ror.org/053nqfd77"},{"id":"https://openalex.org/F4320332193","display_name":"Genentech","ror":"https://ror.org/04gndp242"},{"id":"https://openalex.org/F4320333648","display_name":"Pharmacyclics","ror":"https://ror.org/03hm8w204"},{"id":"https://openalex.org/F4320337351","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4383755513.pdf","grobid_xml":"https://content.openalex.org/works/W4383755513.grobid-xml"},"referenced_works_count":34,"referenced_works":["https://openalex.org/W1506423591","https://openalex.org/W1531083786","https://openalex.org/W1920955154","https://openalex.org/W1964899672","https://openalex.org/W1971436806","https://openalex.org/W1981609651","https://openalex.org/W1983279602","https://openalex.org/W1994740077","https://openalex.org/W2015796126","https://openalex.org/W2032553162","https://openalex.org/W2038761970","https://openalex.org/W2041122217","https://openalex.org/W2043980011","https://openalex.org/W2047115666","https://openalex.org/W2060690570","https://openalex.org/W2082685557","https://openalex.org/W2088277062","https://openalex.org/W2088612710","https://openalex.org/W2094925578","https://openalex.org/W2097007474","https://openalex.org/W2116468952","https://openalex.org/W2124019532","https://openalex.org/W2164180280","https://openalex.org/W2169456326","https://openalex.org/W2177948763","https://openalex.org/W2179438025","https://openalex.org/W2280585894","https://openalex.org/W2338693134","https://openalex.org/W2799170276","https://openalex.org/W2940785776","https://openalex.org/W2974182987","https://openalex.org/W2999901895","https://openalex.org/W3009351592","https://openalex.org/W4282976889"],"related_works":["https://openalex.org/W4294770977","https://openalex.org/W3095908799","https://openalex.org/W4408054269","https://openalex.org/W2590847956","https://openalex.org/W3195083678","https://openalex.org/W2160892014","https://openalex.org/W2082685557","https://openalex.org/W2023418231","https://openalex.org/W2261122747","https://openalex.org/W2183229102"],"abstract_inverted_index":{"The":[0,81],"importance":[1],"of":[2,50,60,72,100,114,130,154,172,186,221],"the":[3,41,48,84,128,155,173],"stromal":[4],"microenvironment":[5,34],"in":[6,21,44,83,92,127,180,202],"chronic":[7],"lymphocytic":[8],"leukemia":[9],"(CLL)":[10],"pathogenesis":[11],"and":[12,32,176,192,215],"drug":[13],"resistance":[14],"is":[15],"well":[16],"established.":[17],"Despite":[18],"recent":[19],"advances":[20],"CLL":[22,31,55,73,90,101,115,139,157,222],"therapy,":[23],"identifying":[24],"novel":[25],"ways":[26],"to":[27,123,144,213],"disrupt":[28],"interactions":[29],"between":[30],"its":[33],"may":[35],"identify":[36],"new":[37],"combination":[38],"partners":[39],"for":[40],"drugs":[42],"currently":[43],"use.":[45],"To":[46],"understand":[47],"role":[49],"microenvironmental":[51,229],"factors":[52],"on":[53,224],"primary":[54],"cells,":[56],"we":[57,110,210],"took":[58],"advantage":[59],"an":[61],"observation":[62],"that":[63,87,119,136],"conditioned":[64],"media":[65],"(CM)":[66],"collected":[67],"from":[68,75],"stroma":[69],"was":[70,97],"protective":[71],"cells":[74,86,102,140],"spontaneous":[76],"cell":[77,125,203],"death":[78,126],"ex":[79,94],"vivo.":[80],"cytokine":[82],"CM-dependent":[85],"most":[88],"supports":[89],"survival":[91],"short-term":[93],"vivo":[95],"culture":[96],"CCL2.":[98],"Pretreatment":[99],"with":[103,184,195,227],"anti-CCL2":[104],"antibody":[105],"enhanced":[106],"venetoclax-mediated":[107],"killing.":[108],"Surprisingly,":[109],"found":[111],"a":[112,152,199],"group":[113],"samples":[116,158],"(9/23":[117],"cases)":[118],"are":[120,141],"less":[121,142],"likely":[122],"undergo":[124],"absence":[129],"CM":[131,225],"support.":[132],"Functional":[133],"studies":[134],"revealed":[135,170],"CM-independent":[137],"(CMI)":[138],"sensitive":[143],"apoptosis":[145],"than":[146],"conventional":[147],"stroma-dependent":[148],"CLL.":[149],"In":[150,208],"addition,":[151],"majority":[153],"CMI":[156,206],"(80%)":[159],"harbored":[160],"unmutated":[161],"immunoglobulin":[162],"heavy-chain":[163],"variable":[164],"(IGHV)":[165],"region.":[166],"Bulk-RNA":[167],"sequence":[168],"analysis":[169],"upregulation":[171],"focal":[174],"adhesion":[175],"RAS":[177],"signaling":[178],"pathways":[179],"this":[181],"group,":[182],"along":[183],"expression":[185],"fms-like":[187],"tyrosine":[188],"kinase":[189],"3":[190],"(FLT3)":[191],"CD135.":[193],"Treatment":[194],"FLT3":[196],"inhibitors":[197],"caused":[198],"significant":[200],"reduction":[201],"viability":[204],"among":[205],"samples.":[207],"summary,":[209],"were":[211],"able":[212],"discriminate":[214],"target":[216],"2":[217],"biologically":[218],"distinct":[219,228],"subgroups":[220],"based":[223],"dependence":[226],"vulnerabilities.":[230]},"counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":2}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2023-07-11T00:00:00"}